Humedix Shares AestheFill Procedure Strategy at Live Academy
Humedix joined the 2026 Korean Society of Aesthetic, Obesity and Regenerative Medicine 2nd Live Academy and presented a session on AestheFill procedure strategy.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Humedix said on September 1 that it had participated in the academy recently held at Konkuk University Hospital. The program was organized for physicians practicing in aesthetic, obesity and regenerative medicine.
The company's session focused on AestheFill, whose main ingredient is poly-D,L-lactic acid, or PDLLA. Humedix described collagen stimulation as the product's principal mechanism and used the session to share procedure strategy.
What the academy session covered
Humedix participated in the AestheFill session during the academy's second live program. The common development across the reports was the company's presentation of procedure strategy for the PDLLA-based product.
Park Shin-hye, director of Miho Clinic, led the session. The reports identified Park as a senior aesthetic-medicine physician and the Yeongnam branch head of the Korean Academy of Aesthetic Medicine.
Evidence limits and patient context
The reports describe participation in an educational session, not results from a clinical study. The Korean medical trade papers did not specify effectiveness rates, side effects, recovery time, costs or patient outcomes.
A conference presentation alone cannot determine whether a procedure suits a particular person. Individual variation may affect treatment planning, possible side effects and recovery, so patients should consult a qualified physician for an assessment based on their health and goals.
Questions for a consultation
A patient considering a PDLLA-based procedure can ask how collagen stimulation relates to the proposed treatment plan and why that approach is being considered. The physician should connect the explanation to the patient's medical history and expectations.
The consultation should also address likely individual variation, possible side effects, expected recovery considerations and alternatives. These patient-specific questions go beyond the academy announcement but are relevant before making a treatment decision.
Frequently asked questions
What did Humedix share at the academy?
Humedix shared procedure strategy during a session devoted to AestheFill at the 2026 academy. The session presented the product as PDLLA-based and described collagen stimulation as its principal mechanism.
Who presented the AestheFill session?
Miho Clinic director Park Shin-hye presented the session. The reports identified Park as a senior aesthetic-medicine physician and the Yeongnam branch head of the Korean Academy of Aesthetic Medicine.
Does the academy presentation show how well the procedure works?
No effectiveness rate or patient outcome was reported with the academy announcement. Patients should consult a qualified physician about expected benefits, individual variation, side effects and recovery before making a decision.
Questions to take to your physician
- Why are you considering a PDLLA-based procedure for my goals?
- How does collagen stimulation relate to the proposed treatment plan?
- Which side effects should I discuss based on my medical history?
- What recovery considerations and individual variation could apply to me?
- What alternatives should I compare before deciding?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
